{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Intravascular+Large+B-Cell+Lymphoma", "query": { "condition": "Intravascular Large B-Cell Lymphoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 8, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T09:45:59.089Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02924402", "title": "Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Non-Hodgkins Lymphoma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "XmAb13676", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2016-10", "completion_date": "2024-04", "has_results": false, "last_update_posted_date": "2024-11-13", "last_synced_at": "2026-05-22T09:45:59.089Z", "location_count": 10, "location_summary": "La Jolla, California • Jacksonville, Florida • Atlanta, Georgia + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02924402" }, { "nct_id": "NCT04799275", "title": "Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Ann Arbor Stage III Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma", "Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Grade 3b Follicular Lymphoma", "HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Intravascular Large B-Cell Lymphoma", "Lymphoplasmacytic Lymphoma", "Nodular Lymphocyte Predominant B-Cell Lymphoma", "Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Oral Azacitidine", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Rituximab and Hyaluronidase Human", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "75 Years", "maximum_age": null, "sex": "ALL", "summary": "75 Years and older" }, "enrollment_count": 422, "start_date": "2021-05-20", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-05-22T09:45:59.089Z", "location_count": 176, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 136 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04799275" }, { "nct_id": "NCT06736613", "title": "A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma", "High-grade B-cell Lymphoma", "Stage III High Grade B-Cell Lymphoma", "Stage IV High Grade B-Cell Lymphoma", "DLBCL - Diffuse Large B Cell Lymphoma", "Intravascular Large B-Cell Lymphoma", "Diffuse Large B Cell Lymphoma of Breast", "Diffuse Large B Cell Lymphoma of Testis", "HIV-associated Diffuse Large B Cell Lymphoma", "Double Expressor DLBCL" ], "interventions": [ { "name": "Cerebral Spinal Fluid ctDNA", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2024-12-11", "completion_date": "2027-12-11", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-05-22T09:45:59.089Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06736613" }, { "nct_id": "NCT03704714", "title": "Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Aggressive Non-Hodgkin Lymphoma", "B-Cell Non-Hodgkin Lymphoma", "CD20 Positive", "Diffuse Large B-Cell Lymphoma Unclassifiable", "Intravascular Large B-Cell Lymphoma", "Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2018-11-20", "completion_date": "2025-06-11", "has_results": false, "last_update_posted_date": "2022-08-15", "last_synced_at": "2026-05-22T09:45:59.089Z", "location_count": 4, "location_summary": "Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lake Forest", "state": "Illinois" }, { "city": "Warrenville", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03704714" }, { "nct_id": "NCT05202782", "title": "Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Large B-Cell Lymphoma With IRF4 Rearrangement", "Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Recurrent Intravascular Large B-Cell Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Recurrent Transformed B-Cell Non-Hodgkin Lymphoma", "Refractory Aggressive B-Cell Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory Intravascular Large B-Cell Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Refractory Transformed B-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Chimeric Antigen Receptor T-Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Zanubrutinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2022-03-21", "completion_date": "2029-10-09", "has_results": false, "last_update_posted_date": "2024-10-16", "last_synced_at": "2026-05-22T09:45:59.089Z", "location_count": 2, "location_summary": "Chicago, Illinois • Milwaukee, Wisconsin", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05202782" }, { "nct_id": "NCT03038672", "title": "Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ALK-Positive Large B-Cell Lymphoma", "Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "EBV-Positive Mucocutaneous Ulcer", "HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Intravascular Large B-Cell Lymphoma", "Large B-Cell Lymphoma With 11q Aberration", "Large B-Cell Lymphoma With IRF4 Rearrangement", "Plasmablastic Lymphoma", "Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System", "Primary Effusion Lymphoma", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Burkitt Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Gray-Zone Lymphoma", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Recurrent Lymphomatoid Granulomatosis", "Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Recurrent Primary Mediastinal Large B-Cell Lymphoma", "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Burkitt Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Gray-Zone Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Refractory Primary Mediastinal Large B-Cell Lymphoma", "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Varlilumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2018-12-21", "completion_date": "2026-10-24", "has_results": true, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-05-22T09:45:59.089Z", "location_count": 33, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03038672" }, { "nct_id": "NCT05507541", "title": "TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent ALK Positive Large B-Cell Lymphoma", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Grade 3b Follicular Lymphoma", "Recurrent High Grade B-Cell Lymphoma", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Intravascular Large B-Cell Lymphoma", "Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Refractory ALK Positive Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory Grade 3b Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified", "Refractory Intravascular Large B-Cell Lymphoma", "Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Refractory Primary Mediastinal Large B-Cell Lymphoma", "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Recurrent Gray Zone Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ontorpacept", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Maplirpacept", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2023-04-19", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-05-22T09:45:59.089Z", "location_count": 2, "location_summary": "Iowa City, Iowa • Rochester, Minnesota", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05507541" }, { "nct_id": "NCT06834373", "title": "Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Large B-Cell Lymphoma With IRF4 Rearrangement", "Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma", "Recurrent ALK-Positive Large B-Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Grade 3b Follicular Lymphoma", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements", "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Intravascular Large B-Cell Lymphoma", "Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Recurrent Primary Mediastinal Large B-Cell Lymphoma", "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Recurrent Transformed Non-Hodgkin Lymphoma", "Refractory Aggressive B-Cell Non-Hodgkin Lymphoma", "Refractory ALK-Positive Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory Grade 3b Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements", "Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified", "Refractory Intravascular Large B-Cell Lymphoma", "Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Refractory Primary Mediastinal Large B-Cell Lymphoma", "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Refractory Transformed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Chimeric Antigen Receptor T-Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Golcadomide", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2025-04-02", "completion_date": "2027-03-03", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-05-22T09:45:59.089Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Albert Lea", "state": "Minnesota" }, { "city": "Mankato", "state": "Minnesota" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06834373" } ] }